Brokers Set Expectations for Humana's Q3 Earnings (NYSE:HUM)

Key Points

• Zacks Research cut Humana’s Q3 2026 EPS estimate to a loss of $1.18 from a prior forecast of $0.08, while maintaining a “Hold” rating.
• Analyst sentiment remains mixed: Humana has a consensus “Hold” rating from 30 analysts, with a consensus price target of $395.22.
• Humana’s latest quarterly results exceeded expectations, with EPS of $7.61 versus $7.27 expected and revenue up 26.2% year over year to $40.89 billion; institutional investors own 92.38% of the stock.

Humana Inc. (NYSE:HUM - Free Report) - Research analysts at Zacks Research lowered their Q3 2026 earnings per share estimates for Humana in a note issued to investors on Wednesday, August 12th. Zacks Research analyst Team now forecasts that the insurance provider will post earnings of ($1.18) per share for the quarter, down from their previous estimate of $0.08. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Humana's current full-year earnings is $9.09 per share. Zacks Research also issued estimates for Humana's Q4 2026 earnings at ($7.74) EPS, FY2026 earnings at $9.00 EPS, Q2 2027 earnings at $5.27 EPS, Q3 2027 earnings at ($1.23) EPS, Q4 2027 earnings at ($2.10) EPS, FY2027 earnings at $10.98 EPS, Q1 2028 earnings at $11.53 EPS, Q2 2028 earnings at $6.74 EPS and FY2028 earnings at $30.30 EPS.

Several other research firms have also recently weighed in on HUM. William Blair initiated coverage on Humana in a report on Wednesday, May 20th. They issued an "outperform" rating on the stock. Seaport Research Partners lowered shares of Humana to a "neutral" rating in a report on Wednesday, May 20th. Robert W. Baird set a $390.00 target price on Humana in a research note on Thursday, July 30th. Barclays raised their price objective on Humana from $344.00 to $407.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Finally, Sanford C. Bernstein restated an "outperform" rating and issued a $425.00 price objective on shares of Humana in a report on Wednesday, June 3rd. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Humana presently has a consensus rating of "Hold" and a consensus target price of $395.22.

Humana Trading Down 1.1%

Humana stock opened at $384.50 on Friday. The stock has a market cap of $46.17 billion, a P/E ratio of 36.38, a PEG ratio of 2.22 and a beta of 0.72. Humana has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The firm's fifty day moving average price is $381.25 and its 200-day moving average price is $274.88. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, beating the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The firm had revenue of $40.89 billion for the quarter, compared to analysts' expectations of $40.58 billion. During the same period in the prior year, the business posted $6.27 earnings per share. The company's revenue was up 26.2% on a year-over-year basis.

Institutional Trading of Humana

A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Wilkerson Advisory Group LLC lifted its holdings in shares of Humana by 24.6% during the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider's stock valued at $66,000 after purchasing an additional 33 shares during the last quarter. Bogart Wealth LLC raised its stake in Humana by 192.0% during the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after buying an additional 48 shares during the last quarter. Fiduciary Alliance LLC lifted its holdings in shares of Humana by 0.9% during the 1st quarter. Fiduciary Alliance LLC now owns 5,628 shares of the insurance provider's stock valued at $976,000 after buying an additional 49 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of Humana by 1.6% in the 4th quarter. Sanctuary Advisors LLC now owns 3,389 shares of the insurance provider's stock worth $868,000 after buying an additional 52 shares during the last quarter. Finally, Horizon Investments LLC grew its holdings in shares of Humana by 2.5% in the fourth quarter. Horizon Investments LLC now owns 2,236 shares of the insurance provider's stock worth $573,000 after acquiring an additional 55 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana News Summary

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Wall Street analysts are moderately optimistic about Humana’s prospects after the stock outperformed the broader market over the past year, providing a supportive backdrop for investor sentiment. Do Wall Street Analysts Like Humana Stock?
• Positive Sentiment: Zacks Research raised its first-quarter 2027 earnings-per-share forecast to $9.04 from $8.70. The increase suggests improved expectations for Humana’s near-term operating performance, despite the firm retaining a Hold rating. Humana earnings estimate update
• Positive Sentiment: Humana is partnering with Cityblock Health to support low-income and dual-eligible Medicare Advantage members. The initiative could strengthen care coordination and outcomes in an important, higher-need segment. Humana teams with Cityblock
• Positive Sentiment: A HealthStream agreement will fund 1,000 caregiver scholarships and provide recruitment and retention tools in Indiana, potentially helping Humana address staffing needs at its CenterWell and care-delivery operations. Humana HealthStream deal

Humana Company Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source